Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study
Metformin may prevent colorectal cancer via the AMPKγ1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials.
Authors
- Celine Sze Ling Chui (ORCID: https://orcid.org/0000-0003-1513-8726)
- Shan Luo (ORCID: https://orcid.org/0000-0003-4760-0372)
- Eric Yuk Fai Wan (ORCID: https://orcid.org/0000-0002-6275-1147)
- C. Mary Schooling (ORCID: https://orcid.org/0000-0001-9933-5887)
- Shiu Lun Au Yeung
- Jie Zheng
- Ian Chi Kei Wong
- Xingyu Shen
Institutions
- Macau University of Science and Technology (MO)
- Department of Health (CN)
- Aston University (GB)
- City University of New York (US)
- Shanghai Jiao Tong University (CN)
- University of Macau (MO)
- Ruijin Hospital (CN)
- University of Bristol (GB)
- Primary HealthCare (MT)
- Institute for Advanced Study (DE)
- University of Hong Kong (HK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-02-27
- DOI
- https://doi.org/10.1111/dom.70598
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00